Market Research Logo

RNAi Technologies and Global Markets

RNAi Technologies and Global Markets

The global market for RNA Interference technologies is expected to grow from $262.1 million in 2015 to $392.6 million in 2020, registering a compound annual growth rate (CAGR) of 8.4%.

This report provides:
An overview of the global market for RNAi technologies which are used in the areas of drug delivery, therapeutics, and diagnostics
Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
A breakdown of the technologies: RNAi for drug delivery (by nanoparticle delivery, nucleic acid delivery, aptamer delivery); RNAi for drug discovery and therapeutics (by diseases); RNAi for disease diagnostics and biomarker development (by diseases); and RNAi for reagents, research tools, and other applications (by application)
Examination of significant deals in the RNAi technologies sector during the last decade
A look at commercial opportunities in the RNAi research tools and reagents, drug development, diagnostic, and agriculture markets
Profiles of major players in the industry


SCOPE OF THE STUDY

BCC Research conducted the market assessment, the global and regional breakdown of sales data, market projection for the commercial RNAi technologies, application of the techniques in commercial sector as well as in research and development. Further, BCC Research offers the details of new developments, patent analysis, market leaders and market share, etc. for the RNAi technologies and its applications.

The report summarizes the global RNAi technologies market by category and by region. The RNAi market is analyzed based on RNAi research tools and reagents as well as on RNAi diagnostics. The research tools and reagents and therapeutics considered in this report are mainly for small/short interfering RNAs (siRNAs) and diagnostics are mainly based on microRNAs (miRNAs).

MicroRNA (miRNA) research tools, services, drug discovery etc. are excluded from this report; however, these areas are worth a separate report and thus are analyzed in BCC Research report BIO115B in detail. U.S. and non-U.S. markets are considered for the geographical market analysis. The prospective application of RNAi therapeutics in various disease classifications such as oncological, cardiovascular, neurodegenerative, ophthalmologic and others are discussed. The application and progress of RNAi technologies in agriculture is also discussed in this report.

BCC Research verified the sales data for the global and regional RNAi markets for the present and projected values through statistical analysis. The tools/technology details in the report are based on their present and their prospective application and suitability.

CHAPTER 1 INTRODUCTION
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)
CHAPTER 3 OVERVIEW
RIBONUCLEIC ACID (RNA)
EVOLUTION OF RNA
TABLE 1 EVOLUTION OF RNA
RNA INTERFERENCE (RNAI)
MECHANISM OF ACTION OF RNA INTERFERENCE
MicroRNA (miRNA)
TABLE 2 MICRORNA (MIRNA) DATABASES
Short Interfering RNA (siRNA)
TABLE 3 SHORT/SMALL INTERFERING RNA (SIRNA) DATABASES
Small Hairpin RNA (shRNA)
Piwi-Interacting RNA (piRNA)
TABLE 4 PIWI-INTERACTING RNA (PIRNA) DATABASES
RNA INTERFERENCE DRUG DELIVERY
SYSTEMIC ELIMINATION OF SIRNA
SIRNA STABILITY IN BLOODSTREAM
RETICULOENDOTHELIAL SYSTEM (RES) ENTRAPMENT
VASCULAR ENDOTHELIUM
DIFFUSION
PLASMA MEMBRANE
ENDOSOMAL ENTRAPMENT
NANO-CARRIER MEDIATED TOXICITY
METHODS OF RNA INTERFERENCE DRUG DELIVERY SYSTEMS
Physical RNAi Delivery Methods
Hydrodynamic Injection
Electroporation
Vector-Based RNAi Delivery Methods
Plasmid Vector RNAi Delivery
Virus Vector RNAi Delivery
Carrier-Based Nonviral RNAi Delivery
Cationic Cell-Penetrating Peptide (CPP)
Aptamer
Lipid-Based siRNA Delivery
TABLE 5 STABILIZATION METHODS FOR LIPID BASED SIRNA
DELIVERY SYSTEM
Polymer- and Peptide-Based Vector
Lipid-Polymer Combination
Dendrimers
Phi29 Packaging RNA
Mesoporous Silica Nanoparticles
Antibodies
Stem Cell
Light-Controlled Delivery
Quaternized Starch Based Carrier
RNAI DRUG DISCOVERY AND DEVELOPMENT
RNA-BASED THERAPIES
Antisense RNA Therapy
Ribosome RNA Therapy
Aptamer RNA Therapy
Messenger RNA (mRNA) Therapeutics
RNAi Therapeutics
Drug Discovery
Targeting miRNA Processes
Delivering Designed siRNAs Into Cells
Drug Target Validation
Designing RNAi Therapeutics
Sequence Selection
Chemical and Structure Modification
Drug Development
RNAi Instability
Off-Target Effects
Innate/Intrinsic Immune Response
Delivery Material Toxicity
Saturation of RNAi Machinery
OTHER POTENTIAL APPLICATIONS OF RNA INTERFERENCE
DIAGNOSTICS
AGRICULTURE
CHAPTER 4 NEW DEVELOPMENTS AND REGULATORY ACTIVITY
NEW DEVELOPMENTS
TABLE 6 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF RNAI
THERAPEUTICS AND TECHNOLOGIES AS OF SEPTEMBER 2015
REGULATORY ASPECTS
REGULATORY DEVELOPMENTS
COLLABORATIVE TRIALS AND FUTURE ACTIVITIES
CHAPTER 5 MARKET ANALYSIS
MARKET BY TECHNOLOGY
TABLE 7 GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
FIGURE 1 GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)
MARKET SHARE
TABLE 8 MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
FIGURE 2 MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
RNA INTERFERENCE RESEARCH TOOLS AND REAGENTS
RNAi Research Tools and Constructs
TABLE 9 MODIFICATIONS OF SIRNA
TABLE 10 RNAI VECTORS
Reagents
Market Overview
Market Revenue
TABLE 11 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, THROUGH 2020 ($ MILLIONS)
FIGURE 3 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, 2013-2020 ($ MILLIONS)
Market Share
TABLE 12 MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
FIGURE 4 MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
RNAI INTERFERENCE THERAPEUTICS
TABLE 13 DISEASE-SPECIFIC TARGET GENES/PROTEINS FOR RNAI THERAPEUTICS
GLOBAL PHARMACEUTICAL MARKET
TABLE 14 GLOBAL PHARMACEUTICAL MARKET, THROUGH 2020 ($ BILLIONS)
FIGURE 5 GLOBAL PHARMACEUTICAL SALES MARKET,2013-2020 ($ BILLIONS)
Market Share of Pharmaceutical Products by Region
TABLE 15 GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
FIGURE 6 GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
Sales of Top Pharmaceutical Companies
TABLE 16 TOP GLOBAL PHARMACEUTICAL COMPANIES BY SALES, 2014 ($ MILLIONS)
Diseases
Cardiovascular Disease
Pulmonary Disease
Central Nervous System (CNS) Disease
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Oncology
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Liver Cancer
Renal Cancer
Colon Cancer
Lung Cancer
Brain Tumor
Prostate Cancer
Age-Related Macular Degeneration (AMD)
Global Outlook of Therapeutic Spending for Certain Diseases
TABLE 17 GLOBAL OUTLOOK OF THERAPEUTIC SPENDING BY DISEASE, THROUGH 2018 ($ BILLION/%)
Market Overview
RNAI DIAGNOSTICS
TABLE 18 NUMBER OF PUBLICATIONS ASSOCIATED WITH MIRNA AND DISEASES, OCTOBER 2015
miRNA in Cancer Diagnostics
TABLE 19 MIRNA IN VARIOUS CANCER TYPES
TABLE 20 MIRNA AND TARGET GENE PAIRS IN VARIOUS CANCER
TYPES
miRNAs as Diagnostic, Prognostic and Predictive Biomarkers
TABLE 21 BIOMARKERS IN VARIOUS CANCER TYPES
Market Overview
Market Revenue
TABLE 22 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, THROUGH 2020 ($ MILLIONS)
FIGURE 7 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, 2013-2020 ($ MILLIONS)
Revenue for Global mRNA Research Tools Market
TABLE 23 GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, THROUGH 2020 ($ MILLIONS)
FIGURE 8 GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS,2013-2020 ($ MILLIONS)
RNA INTERFERENCE IN AGRICULTURE
Virus Control Through RNAi
Safety Concerns
TABLE 24 SAFETY ISSUES WITH RNAI CROP IMPROVEMENT
RNAi In Crops
TABLE 25 PLANT IMPROVEMENT AREAS THROUGH RNAI TECHNOLOGIES
TABLE 26 REGIONS, GENES AND APPLICATION OF RNAI-TARGETING ORGANISMS FOR IMPROVEMENT OF CROPS
RNAi In Aquaculture
Market Overview
MARKET BY REGION
MARKET OVERVIEW
MARKET REVENUE
RNAi Research Tools and Reagents
TABLE 27 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 9 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2013-2020 ($ MILLIONS)
Market Share
TABLE 28 GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
FIGURE 10 GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
RNAi Diagnostics
TABLE 29 GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 11 GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, 2013-2020 ($ MILLIONS)
Market Share
TABLE 30 GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)
FIGURE 12 GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)
CHAPTER 6 INDUSTRY STRUCTURE
RNAI RESEARCH TOOLS AND REAGENTS
MARKET LEADERS
TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF RNAI RESEARCH TOOLS AND REAGENTS, 2014
MARKET SHARES
TABLE 32 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
FIGURE 13 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
RNAI DIAGNOSTICS
MARKET LEADERS
TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF RNAI DIAGNOSTICS, 2014
MARKET SHARES
TABLE 34 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)
FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)
CHAPTER 7 PATENT ANALYSIS
PATENTS BY YEAR
TABLE 35 TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
FIGURE 15 TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
PATENTS BY COUNTRY FOR RNA INTERFERENCE TECHNOLOGIES
TABLE 36 NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015
TABLE 37 PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
FIGURE 16 PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
PATENTS BY COMPANY FOR RNA INTERFERENCE TECHNOLOGIES
TABLE 38 NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COMPANY, 2013-AUGUST 2015
PATENTS BY ASSIGNEE FOR RNA INTERFERENCE TECHNOLOGIES
TABLE 39 NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST 2015
FIGURE 17 NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST, 2015
CHAPTER 8 CURRENT STATUS
INNOVATIVE TECHNOLOGIES AND PLATFORMS FOR RNA INTERFERENCE
DYNAMIC POLYCONJUGATE (DPC) PLATFORM-ARROWHEAD RESEARCH CORP.)
CONJUGATE DELIVERY PLATFORMS - ESC-GALNAC-CONJUGATE (ALNYLAM PHARMACEUTICALS INC.)
LIPID NANOPARTICLE (LNP) TECHNOLOGY (ARBUTUS BIOPHARMA CORP)
SIRNA TECHNOLOGY PLATFORM (QUARK PHARMACEUTICALS INC.)
MODIFIED MESSENGER RNA THERAPEUTICS PLATFORM (MODERNA THERAPEUTICS)
RNAI TECHNOLOGY PLATFORMS (GE DHARMACON)
On-TARGETplus siRNAs
Reverse Transfection Format (RTF) siRNA Libraries
Cherry-Pick RNAi Libraries
Human siRNA Libraries
Custom siRNA Synthesis
Accell siRNA
Mouse Accell siRNA Library - Protein Kinases
siGENOME siRNAs
Lincode siRNAs
Lincode siRNA Libraries
SMARTvector Lentiviral shRNA
SMARTvector Inducible Lentiviral shRNA
SMARTvector Lentiviral shRNA Pooled Libraries
GIPZ Lentiviral shRNA
TRIPZ Inducible Lentiviral shRNA
The RNAi Consortium (TRC) Lentiviral shRNA Library
Decode Pooled Lentiviral shRNA Screening Libraries and Reagents
Viral Packaging Kits
siRNA and microRNA Transfection Reagents
DharmaFECT Duo Transfection Reagent
RNAI TECHNOLOGIES (THERMO FISHER SCIENTIFIC)
Silencer Select siRNA
Silencer Select siRNA Libraries
Stealth RNAi siRNAs
BLOCK-iT siRNAs
Controls for RNAi Mechanism
RNAI TOOLS FROM SIGMA-ALDRICH
MISSION siRNA
Pre-arrayed siRNA Libraries
MISSION In Vivo Quality and iScale Oligos siRNA
N-TER Nanoparticle siRNA Transfection System
siRNA Controls (Positive and Negative)
MISSION shRNA Library
MISSION Lentiviral Controls
MISSION esiRNA
MISSION Human miRNA Mimics
LOCKED NUCLEIC ACID (LNA) PLATFORM (ROCHE [SANTARIS PHARMA])
TRIFECTA RNAI KIT (INTEGRATED DNA TECHNOLOGIES)
PSITEST SYSTEM (INVIVOGEN)
SELF-DELIVERABLE RNAI TECHNOLOGY (ADVIRNA)
RNAI TECHNOLOGIES (BIONEER CORP)
AccuTarget Libraries
AccuTarget Control siRNAs from Bioneer
AccuTarget Human miRNA Mimic and Inhibitor Library
Self-Assembled Micelle Inhibitory RNA (SAMiRNA)
POOLED LENTIVIRAL LIBRARIES (CELLECTA INC.)
NANOPARTICLE-DRUG CONJUGATES (NDCS) (CERULEAN PHARMA INC.)
ALLSTARS RNAI CONTROLS (QIAGEN N.V.)
RNAI TECHNOLOGIES (APPLIED BIOLOGICAL MATERIALS)
siRNA Adeno-Associated Virus (AAV)
iLenti RNAi Expression System
LIPID-ENABLED AND UNLOCKED NUCLEIC ACID MODIFIED RNA DELIVERY TECHNOLOGY (ARCTURUS THERAPEUTICS, INC.)
ELASTIN-LIKE POLYPEPTIDE (ELP) NANOPARTICLES (PEPTIMED INC.)
MICRORNA-BASED DIAGNOSTIC TESTS (ROSETTA GENOMICS)
The Rosetta Cancer Origin Test
The Rosetta Lung Cancer Test
The Rosetta Kidney Cancer Test
The Rosetta Mesothelioma Test
ATURNAI (SILENCE THERAPEUTICS)
DSIRNA-EX-CONJUGATES (DICERNA PHARMACEUTICALS INC.)
LODER (SILENSEED LTD.)
FACTORS AFFECTING THE RNA INTERFERENCE MARKET
CURRENT DRIVERS FOR THE RNA INTERFERENCE TECHNOLOGY MARKET
MERGER AND ACQUISITION ACTIVITIES
FUNDING FOR DEVELOPMENT OF RNA INTERFERENCE THERAPEUTICS AND TECHNOLOGIES
TABLE 40 FUNDING FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015
TABLE 41 INVESTMENTS FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015
CHAPTER 9 COMPANY PROFILES
ADVIRNA
ALNYLAM PHARMACEUTICALS, INC.
APEIRON BIOLOGICS AG
APPLIED BIOLOGICAL MATERIALS, INC.
ARBUTUS BIOPHARMA CORP. (PREVIOUSLY TEKMIRA PHARMACEUTICALS CORP.)
ARCTURUS THERAPEUTICS, INC.
ARROWHEAD RESEARCH CORP.
ASCLETIS INC.
BENITEC BIOPHARMA LTD.
BIOGEN IDEC, INC.
BIOMICS BIOTECHNOLOGIES CO. LTD.
BIONEER CORP.
CELLECTA, INC.
CERULEAN PHARMA, INC.
DICERNA PHARMACEUTICALS, INC.
EXIQON A/S
F. HOFFMANN-LA ROCHE AG (ROCHE)
GENERAL ELECTRIC CO.
INTEGRATED DNA TECHNOLOGIES, INC.
INVIVOGEN
ISIS PHARMACEUTICALS, INC.
MARINA BIOTECH, INC.
MODERNA THERAPEUTICS
MONSANTO CO.
NITTO DENKO CORP.
PEPTIMED INC.
QIAGEN N.V.
QUARK PHARMACEUTICALS, INC.
REGULUS THERAPEUTICS
ROSETTA GENOMICS LTD.
RXI PHARMACEUTICALS CORP.
SANOFI
SIGMA-ALDRICH
SILENCE THERAPEUTICS PLC.
SILENSEED LTD.
SOLSTICE BIOLOGICS
SOMAGENICS, INC.
SUMITOMO DAINIPPON PHARMA CO. LTD.
SYNGENTA INTERNATIONAL AG
THE NATIONAL INSTITUTES OF HEALTH (NIH)
THE RNAI CONSORTIUM AT BROAD INSTITUTE OF MIT AND HARVARD
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
THERMO FISHER SCIENTIFIC, INC.
ZELTIA GROUP
CHAPTER 10 APPENDIX
GLOSSARY AND ABBREVIATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report